Pfizer accuses Novo Nordisk of stalling $9 billion Metsera bid in an antitrust lawsuit. Novo and Metsera deny claims. Novo launched seventh bid after board overhaul. Metsera deems Novo’s offer superior, prompting Pfizer to sue. Metsera accuses Pfizer of gaming the schedule. Novo confident in following merger agreement.

Pfizer files second lawsuit alleging Novo aims to delay market entry for obesity drugs targeting GLP-1 protein. Pfizer’s deal with Metsera had a nine-month timeline and antitrust review termination. Novo accused of blocking Metsera’s drug development progress to protect market share. Metsera shares fell 3.7% after the legal battle escalated.

Metsera developing monthly obesity drug. Pfizer sees potential in $150 billion obesity market. Metsera’s experimental therapies could generate $5 billion in sales. Legal battle continues in Delaware courts. Novo confident in following merger agreement. Novo denies accusations of delaying competition.

Read more at Yahoo Finance: Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit